HC Wainwright Raises Price Target for BrainsWay to $17.00 Amidst "Buy" Rating

BrainsWay (BWAY) has received a "Buy" rating and a $17.00 price target from HC Wainwright & Co., a 6.25% increase from the previous target of $16.00. The company's Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology is used to treat mental health disorders. Analysts forecast an average target price of $19.00 with a high estimate of $19.00 and a low estimate of $19.00, indicating a 49.61% upside from the current price.

In a significant move for the healthcare technology sector, BrainsWay (BWAY) has received a "Buy" rating and a new price target of $17.00 from HC Wainwright & Co., marking a 6.25% increase from the previous target of $16.00 [1]. This bullish outlook reflects the analyst's confidence in the company's Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology, which is used to treat mental health disorders.

The new price target of $17.00 positions BrainsWay at an average target price of $19.00, with a high estimate of $19.00 and a low estimate of $19.00, indicating a potential 49.61% upside from the current price. This positive sentiment is driven by the company's strong financial performance and its growing market share in the noninvasive neuromodulation space.

In its earnings call for the second quarter of 2025, BrainsWay reported record quarterly revenue of $12.6 million, a 26% increase year-over-year, and shipped 88 Deep TMS systems, representing a 35% increase in installations. The company's installed base now stands at 1,522 systems, underscoring its leadership position in the market. Additionally, multi-year lease agreements now represent 70% of customer engagements, contributing to a $62 million backlog of remaining performance obligations and providing clear revenue visibility [2].

BrainsWay's strategic focus on elevating market awareness of Deep TMS, advancing its R&D roadmap, and broadening patient access through global expansion and health system integration has positioned it as a scalable growth platform. The company's regulatory approvals and clinical data continue to set Deep TMS apart, enhancing its competitive edge.

Institutional investors have shown strong interest in BrainsWay, with the company's stock receiving a "Buy" rating from multiple analysts. This positive sentiment is likely to drive further investment and support the company's growth trajectory.

References:
[1] https://www.marketbeat.com/earnings/reports/2025-8-13-brainsway-ltd-stock/
[2] https://www.marketbeat.com/earnings/reports/2025-8-13-brainsway-ltd-stock/